ArticleMultiple sclerosis international2011
Potential impact of B cells on T cell function in multiple sclerosis.
Article in Multiple sclerosis international, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed.
- The real-world effectiveness and safety of off-label rituximab in a large cohort of Middle Eastern multiple sclerosis patients.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2026Observational
- Rituximab for the treatment of multiple sclerosis: a review.Journal of neurology · 2022Review
- Comparison of The Expression of miR-326 between Interferon beta Responders and Non-Responders in Relapsing-Remitting Multiple Sclerosis.Cell journal · 2020Article
- B Cell and CD4 T Cell Interactions Promote Development of Atherosclerosis.Frontiers in immunology · 2019Article
- Effects of IFN-β1a and IFN-β1b treatment on the expression of cytokines, inducible NOS (NOS type II), and myelin proteins in animal model of multiple sclerosis.Archivum immunologiae et therapiae experimentalis · 2017Article
- miRNAs Participate in MS Pathological Processes and Its Therapeutic Response.Mediators of inflammation · 2016Review
- Single dose of glycoengineered anti-CD19 antibody (MEDI551) disrupts experimental autoimmune encephalomyelitis by inhibiting pathogenic adaptive immune responses in the bone marrow and spinal cord while preserving peripheral regulatory mechanisms.Journal of immunology (Baltimore, Md. : 1950) · 2014Article
- Anti-CD20 inhibits T cell-mediated pathology and microgliosis in the rat brain.Annals of clinical and translational neurology · 2014Article
- Immunomodulatory activity of interferon-beta.Annals of clinical and translational neurology · 2014Review
- Rituximab in idiopathic nephrotic syndrome: does it make sense?Pediatric nephrology (Berlin, Germany) · 2014Review
- The emerging role of autoimmunity in myalgic encephalomyelitis/chronic fatigue syndrome (ME/cfs).Molecular neurobiology · 2014Review
- Review
- MicroRNAs as active players in the pathogenesis of multiple sclerosis.International journal of molecular sciences · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Multiple sclerosis is a chronic debilitating autoimmune disease of the central nervous system. The contribution of B cells in the pathoetiology of MS has recently been highlighted by the emergence of rituximab, an anti-CD20 monoclonal antibody that specifically depletes B cells, as a potent immunomodulatory therapy for the treatment of MS. However, a clearer understanding of the impact B cells have on the neuro-inflammatory component of MS pathogenesis is needed in order to develop novel therapeutics whose affects on B cells would be beneficial and not harmful. Since T cells are known mediators of the pathology of MS, the goal of this review is to summarize what is known about the interactions between B cells and T cells, and how current and emerging immunotherapies may impact B-T cell interactions in MS.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.